人环素和心律失常的风险:系统性审查和元分析
Yomna E Dean1, Hazem Dahshan2, Karam R Motawea1
1Alexandria Medical Center (AMC), Alexandria University, Faculty of Medicine, Alexandria, Egypt.
抗环素化疗显著增加心律失常的风险,包括导电异常和心跳动. 接受 antracyclines 治疗的患者需要ECG 监测,并应考虑预防性治疗.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 有争议的调查结果存在关于Anthracycline使用和心律失常风险.
- 这一元分析评估了人环素治疗与发生心律失常的风险之间的关联.
结论:
- 人环素治疗显著增加心律不整的风险.
- 接受 antracycline 治疗的患者需要进行心电图查,对于容易发生心律失常的人来说,可能需要使用替代药物.
- 建议对预防性抗纤维化和抗失常药物进行进一步的研究.
更多相关视频
23:33The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Mechanism of Cardiac Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
